NewAmsterdam Pharma Company NV’s recent filing unveils that its Affiliate Douglas F Kling acquired Company’s shares for reported $5.6 million on May 15 ’25. In the deal valued at $18.75 per share,298,612 shares were bought.
Then, NAP PoolCo B.V. bought 1,433,193 shares, generating $21,669,878 in total proceeds.
Before that, Topper James N bought 1,135 shares. NewAmsterdam Pharma Company NV shares valued at $25,521 were divested by the Director at a price of $22.49 per share. As a result of the transaction, Topper James N now holds 3,013,569 shares, worth roughly $59.52 million.
Stifel initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published on June 10, 2025; the price target was $44. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early June with a ‘”an Overweight”‘ rating. H.C. Wainwright began covering NAMS with “Buy” recommendation on December 30, 2024. TD Cowen started covering the stock on May 15, 2024. It rated NAMS as “a Buy”.
Price Performance Review of NAMS
On Monday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock fall -2.28% to $19.75. Over the last five days, the stock has lost -2.03%. NewAmsterdam Pharma Company NV shares have fallen nearly -23.15% since the year began. Nevertheless, the stocks have fallen -0.25% over the past one year. While a 52-week high of $27.29 was reached on 01/02/25, a 52-week low of $14.06 was recorded on 04/07/25.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 18.77, which if violated will result in even more drops to 17.78. On the upside, there is a resistance level at 20.57. A further resistance level may holdings at 21.38.
The most recent change occurred on March 14, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $35 price target.
